WAVEMAN · COMPANY

COLL · Collegium Pharmaceutical, Inc

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

COLL

Name: COLLEGIUM PHARMACEUTICAL, INC (COLL) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

COLLEGIUM PHARMACEUTICAL, INC

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001267565

FORM 144 · 2☆ WATCH

INSIDER NET · 180D

-$1.3M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

164

13F, latest reported quarter

REVENUE GROWTH

+23.6%

XBRL, annual

NET MARGIN

8.1%

CONVERSIONS · 180D

codes C/M, not in net · $430.4K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$1.3M over 180 days

below 63% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

164 funds added or opened last quarter

more than 81% of Pharma & Biotech

REVENUE

+23.6% year over year

more than 71% of Pharma & Biotech

MARGIN

8.1% net margin

more than 78% of Pharma & Biotech

BUYBACKS

$25.1M repurchased, FY to 2025-12-31

below 58% of Pharma & Biotech

SHORT

15.6% of shares outstanding short · 17.4 days to cover · settled 2026-07-31

more than 90% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$1.3M across 4 people in 180 days.

164 funds added or opened positions in the latest 13F quarter, of 281 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -39.5%

-39.5%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $1.3M sold by insiders over 180 days, 164 funds added last quarter, $791.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, COLLEGIUM PHARMACEUTICAL, INC insiders sold a net $1.3M of stock across 100 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Freund John Gordon

Director

SELL

2026-05-18

20.0

$681

Freund John Gordon

Director

SELL

2026-05-15

4,127.0

$142.5K

Lurker Nancy

Director

SELL

2026-05-13

4,500.0

$161.9K

BOHLIN GAREN G

Director

SELL

2026-05-11

8,700.0

$323.5K

Dieter David

EVP & General Counsel

SELL

2026-03-18

13,976.0

$488.0K

100 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 95 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

5,441,202.0 sh

$197.0M

Jupiter Topco LLC

2,147,072.0 sh

$77.7M

Invesco Ltd.

1,882,499.0 sh

$68.1M

FULLER & THALER ASSET MANAGEMENT, INC.

1,632,781.0 sh

$59.1M

PRINCIPAL FINANCIAL GROUP INC

1,632,360.0 sh

$59.1M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Fallon John A.

FILED 2026-07-17

$497.4K

Fallon John A.

FILED 2026-07-15

$294.0K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Third Avenue Small-Cap Value Fund

$6.1M POSITION · AS OF 2026-04-30

3.1%

Invesco Pharmaceuticals ETF

$7.3M POSITION · AS OF 2026-04-30

2.2%

Invesco Biotechnology & Genome ETF

$5.2M POSITION · AS OF 2026-04-30

2.1%

F/m Emerald Life Sciences Innovation ETF

$2.0M POSITION · AS OF 2026-02-28

2.1%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$5.5M POSITION · AS OF 2026-03-31

1.8%

Miller Market Neutral Income Fund

$4.1M POSITION · AS OF 2026-04-30

1.8%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return · Mr. Karnani

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$1.7M

$7.9M

$3.1M

+125%

+58%

2023

$9.1M

$15.0M

$2.6M

+50%

+19%

2022

$6.9M

$10.5M

$1.8M

+13%

+14%

2021

$7.3M

$5.1M

$2.2M

-9%

+26%

2020

$6.0M

$5.2M

$2.2M

-3%

+26%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$780.6M	$631.4M	$566.8M	$463.9M
GROSS PROFIT	$463.3M	$377.3M	$326.2M	$209.5M
OPERATING INCOME	$179.6M	$169.9M	$167.0M	$33.3M
NET INCOME	$63.0M	$69.0M	$48.0M	$-25.0M
EPS (DILUTED)	1.73	1.86	1.29	-0.74
OPERATING CASH FLOW	$329.3M	$205.0M	$274.7M	$124.2M
CASH	$231.3M	$70.6M	$238.9M	$173.7M
BUYBACKS	$25.1M	$60.0M	$75.0M	$14.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE